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HIV-specific antibody-dependent cell cytotoxicity (ADCC) is likely to be important in 
governing protection from human immunodeficiency virus (HIV) and slowing disease 
progression. Little is known about the ADCC responses to HIV-1 subtype C. We charac-
terized ADCC responses in HIV-1 subtype C-infected Indian subjects with slow disease 
progression and identified the dominant antigenic regions recognized by these antibod-
ies. ADCC responses were measured in plasma from 34 long-term non- progressors 
(LTNPs), who were asymptomatic and maintained CD4 count above 500 cells/mm3 
for the last 7  years in the absence of antiretroviral therapy (ART), and 58 ART naïve 
progressors with CD4 count <500 cells/mm3 against overlapping HIV-1 peptides using 
a flow cytometry-based antibody-dependent natural killer (NK) cell activation assay. The 
assay measured CD107a expression on NK cells as a marker of antibody-dependent 
NK cell activation and IFN-γ secretion by NK cells upon activation. The ADCC epitopes 
were mapped using the matrix of overlapping peptides. Indian LTNPs showed higher 
and broader ADCC responses compared to the progressors. The Env-C and Tat-specific 
ADCC responses were associated with lower plasma viral load, whereas the Env-C 
responses were also associated with higher CD4 counts. Five of 10 LTNP  responders 
targeted epitopes in the V3 region (amino acids 288–330) of Env-C. Additionally, three 
Tat regions were targeted by ADCC antibodies from LTNPs. ADCC responses were 
associated with slow HIV progression in Indian subtype C-infected cohort. The fre-
quently recognized peptides from the V3 loop of Env and the novel epitopes from Tat by 
the LTNPs warrants further study to understand the role of ADCC responses to these 
regions in control and prevention of HIV-1 infection.
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TaBle 1 | Demographic, immunological, and virological characteristics 
of human immunodeficiency virus-infected study participants.
long-term 
non-progressor
Progressors
Number of subjects 34 58
Median age (years) 38.5 35
IQR (35–45) (31–39)
Male/female 11/23 34/24
Years of seropositivity (mean and range) 10.8 years 
(7–19 years)
–
CD4 count at the testing visit (cells/
mm3) [median and IQR]
699 (632–942) 409 (315–456)
Mann–Whitney U-test p < 0.0001
Plasma viral load at testing visit (RNA 
copies/ml) [median and IQR]
2,174  
(422–9,799)
17,148 
(5,543–87,100)
Mann–Whitney U-test < 0.0003
Number of viremic controllers (viral load 
<2,000 RNA copies/ml)
12 0
Number of non-viremic individuals (viral 
load >2,000 RNA copies/ml)
22 58
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inTrODUcTiOn
A vaccine is urgently needed for ultimate success in controlling 
human immunodeficiency virus (HIV) epidemic. However, one 
of the major obstacles in this endeavor is that the correlates of 
immunity to HIV are poorly understood. Fc-mediated functions 
of Env-specific antibodies, such as antibody-dependent cell 
cytotoxicity (ADCC), correlated with protection against HIV 
infection in an RV 144 phase III HIV vaccine trial (1). Further, 
ADCC responses have been associated with protection against 
infection in newborns (2). However, data are scarce on the ADCC 
responses in the individuals infected with different HIV subtypes 
especially infected with Indian strains of HIV-1.
Human immunodeficiency virus-infected individuals who 
are able to maintain CD4 counts above 500 cells/mm3 for 
extended time period, usually more than 7  years of infection 
in the absence of antiretroviral treatment (ART) are commonly 
termed as long-term non-progressors (LTNPs) (3). Although a 
subset of LTNPs generates broadly neutralizing antibodies or 
efficient T cell immunity to HIV, such immune responses do not 
fully explain their slower disease progression (4–6). Fc-mediated 
antibody responses can mediate clearance of infected cells and 
may contribute to slower disease progression (7). However, 
these responses have not been characterized well in subtype 
C-infected Indian subjects. Further, the information on HIV 
epitopes recognized by ADCC antibodies across different HIV 
clades is limited.
We have previously shown that the natural killer (NK) 
cells from Indian LTNPs are functionally competent in lysing 
HIV-infected cells (8). However, the information about ADCC-
mediating antibodies in these patients was not known. Recent 
advances in assays to measure the ability of ADCC antibodies to 
activate NK cells in response to pools of overlapping HIV-1 pep-
tides (9) allowed us to characterize linear peptide ADCC epitopes 
recognized by HIV subtype C-infected Indian subjects. This 
study was undertaken to estimate and characterize the ADCC 
responses for their magnitude and breadth in Indian LTNPs and 
to identify the epitopes recognized by them.
MaTerials anD MeThODs
study Participants
Study participants were identified among the attendees of the 
outpatient clinics of the National AIDS Research Institute who 
visited the clinic regularly for care and support. LTNPs were 
identified as individuals with asymptomatic HIV infection for 
more than 7 years who had stable CD4 counts above 500 cells/μl 
and who had not taken ART (3). Progressors were identified as 
ART-naive HIV-infected patients with CD4 counts <500 cells/μl. 
Thirty-four LTNPs and 58 progressors were enrolled in the study 
along with 14 HIV-uninfected healthy individuals. Demographic, 
immunological, and virological characteristics of 92 HIV+ sub-
jects are shown in Table 1.
The study was approved by the institutional ethical commit-
tee. Participants were enrolled after obtaining written informed 
consent.
aDcc intracellular cytokine staining 
assay (nK cell activation assay)
The ADCC response in the serum/plasma samples of the study 
participants was determined using NK cell activation assay as 
described previously (10). The assay uses CD107a and IFN-γ 
expression by NK cells as a final readout. We preferred this assay, 
although it does not measure the killing of infected target cells, 
as this assay was helpful in allowing us to map the linear epitopes 
recognized by ADCC-mediating antibodies and also captured 
cytokine secretion (IFN-γ), an another important aspect of 
antibody-mediated NK cell activation. Also, it has been recently 
shown that the ADCC activity observed in NK cell activation 
assay correlates significantly with functional killing assays such 
as the rapid fluorometric ADCC assay (11) and other assays 
(12–17). The anti-HIV ADCC responses were assessed against 
consensus envelope [both HIV-1 B and C], Gag (HIV-1C consen-
sus), Pol (HIV-1 B consensus), and accessory proteins: Nef, Vpu, 
Rev, and Tat (HIV-1 B consensus) using pools of 15mer peptides 
overlapping by 11aa (National Institutes of Health AIDS reagent 
program). The detailed description of the peptides and the proce-
dure for preparation of peptide pools is given in Supplementary 
Material. Briefly, 150  µl whole blood from healthy donor (as a 
source of NK cells) and 50 µl of heat-inactivated heparin-anti-
coagulated plasma or serum [final concentration as1:4] from the 
study participants was incubated at 37°C with HIV peptide pools 
(at a final concentration of 1 μg/ml/peptide) for 5 h in the pres-
ence of brefeldin A (10 μg/ml) (Sigma) and monensin (0.68 μl/
ml) (BD Biosciences). After incubation, CD3−CD56dim NK 
cells were gated and analyzed for the expression of intracellular 
IFN-γ and CD107a using fluorescent tagged antibodies [CD3 Per 
Cp: (clone-SK7), CD56 PE-Cy7: (clone-HCD56), and CD107a 
APC H7: (clone-H4A3) (all from Biolegend), and IFN-γ APC: 
(clone-B27) (BD Biosciences)]. The gating strategy is shown in 
Figures  1A–C. Stimulation by purified anti-CD16 monoclonal 
FigUre 1 | gating strategy for antibody-dependent natural killer (nK) cell activation assay. (a–c) Donor blood (as a source of NK cells) was incubated 
with the serum/plasma test samples and human immunodeficiency virus (HIV) peptide pools for 5 h and then analyzed by flow cytometry. The lymphocytes were 
gated using FSC/SSC scatter. The NK cells were identified as CD3−CD56+ cells and assessed for surface CD107a expression and intracellular IFN-γ expression. 
(D) Representative dot plots for positive control (purified anti-CD16). (e) Unstimulated (DMSO equivalent solution) control. (F,g) Representative displays of ADCC 
responder (patient-1) and non-responder (patient-2) to HIV-1 Env-C peptide pool.
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antibody (clone-3g8, at 2.5 μg/ml concentration) was used as a 
positive control (Figure 1D). Plasma samples of all study groups 
incubated with HIV-negative donor blood in the absence of anti-
gen was considered as a negative control for the respective sam-
ple. Mock control containing plasma, HIV-negative donor blood, 
and DMSO equivalent solution was used to negate the effect of 
DMSO that was used to dissolve peptides on NK cell activation 
(Figure 1E). The percentage of activated NK cells as a marker of 
ADCC activity was represented as the sum of the percentage of 
any activated NK cells, expressing only CD107a, both CD107a 
and IFN-γ and only IFN-γ (Figures 1F,G). The percent NK cell 
activation seen in mock stimulation (donor blood (NK cells) and 
test plasma incubated along with DMSO equivalent solution) for 
each sample was subtracted from this sum. The NK cell activation 
in mock control (plasma+ cells without stimulation) ranged from 
0.124 to 4.41% with the mean of 1.48%. The response was consid-
ered to be positive if the following two criteria were fulfilled: (1) 
the total percentage of CD107a and IFN-γ expressing (activated) 
NK cells was more than three times the percentage of activated 
NK cells from the negative control of the respective sample and 
(2) the total percentage of activated NK cells was greater than 
the mean plus two SD of the percent activated NK cells from 14 
HIV-negative donors tested for each of the HIV antigens. The 
interassay variation was found to be <10% as assessed by deter-
mining the % CV for positive control [Anti-CD16 stimulation] 
was 7.18% and negative control [donor blood (source of NK cells) 
without any stimulant] was 9.8%.
Mapping of epitopes recognized by 
aDcc antibodies
The samples of ADCC responders were further used to identify 
linear peptides recognized by ADCC antibodies using the peptide 
matrix pools in NK cell activation assay. The matrix pools were 
designed in such a way that each peptide is present in two different 
pools as described previously (18). The peptide that was common 
in two pools showing that ADCC response was identified as the 
peptide recognized by ADCC antibodies and the recognition of 
the particular peptide was further confirmed by repeating the NK 
cell activation assay using the single peptide. For mapping the 
epitopes, 30 pools for HIV-1 subtype C Env peptides and 10 pools 
for HIV-1 subtype B Tat peptides were used. Details of the pools 
are given in Figures S1A,B in Supplementary Material.
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statistical analysis
Statistical analyses were performed using GraphPad Prism, ver-
sion 5.0 (GraphPad Software, San Diego, CA, USA). Data were 
analyzed by Mann–Whitney U test to compare the magnitude 
of ADCC responses between LTNP and progressor groups. 
Correlation analyses were performed using Spearman correla-
tion between CD4 count, viral load, and magnitude of ADCC 
responses. Fisher’s exact test and chi square tests were used 
to analyze the significance of ADCC responses in different 
categories.
resUlTs
lTnP and Progressor cohorts
Thirty-four HIV-infected individuals who fulfill criteria for LTNP 
were enrolled in the study. As a comparator, we selected 58 pro-
gressor subjects with CD4 T cell counts of <500/μl. The median 
age of LTNPs (median 39  years [IQR 35–45]) and progressors 
(median 35 [IQR 31–39]) was not significantly different. Of the 
34 LTNPs, 23 were female and 11 were male, versus 24 and 34 
among the 58 progressors, respectively. The mean seropositivity 
in LTNP cohort was 10.8 years with a range from 7 to 19 years. 
The CD4 counts of LTNPs at the study visit (median 699 cells/μl 
[IQR 632–942]) were significantly higher than in the progressors 
(median 409 cells/μl [IQR 315–456]) (p < 0.001). As expected, the 
plasma viral load values at the study visits were significantly lower 
in LTNPs (median 2,174 HIV RNA copies/ml [IQR 422–9,799]) 
when compared to the values from progressors (median 17,148 
[IQR 5,543–87,100]) (p = 0.0002) (Table 1).
indian lTnPs have significantly higher 
levels of aDcc responses
A total of 20 of 34 LTNPs (58.8%) and 20 of 58 progressors 
(34.4%) showed antibody-dependent NK cell activation against 
at least one of the HIV overlapping peptide pools. The trend of 
higher magnitude in LTNP was observed in the case of Env-C 
[LTNP mean 18.2%; range 8.4–35%, progressors mean 13.72%; 
range 5.6–24.5%], Tat B [LTNP mean 10.8%; range 5.8–16.4%, 
progressors mean 4.3%], Nef B [LTNP mean 7.6%; range 
4.6–15.87%, progressors mean 5.6%; range 3.5–10.6%], and Vpu 
[LTNP mean 13%; range 5.1–20.8%, progressors mean 11%; 
range 3.6–21%]. Whereas a trend of higher magnitude in pro-
gressors was observed in the case of Env B (LTNP mean 9.36%; 
range 2.8–21%, progressors mean 13.01%; range 2.7–43%) and 
Rev B [LTNP mean 6.2%; range 4–9.2%, progressors mean 9%; 
range 3.7–16.6%]. In the case of Gag C, ADCC responses were 
seen only in the LTNP cohort and only one from progressor 
group showed the ADCC response against Pol B peptide pool 
(Figures  2A,B). The number of LTNPs showing Env-C and 
Gag-specific ADCC responses was also significantly higher than 
among progressors (p < 0.007 and p < 0.016, respectively). The 
number of responders against Tat antigen was also higher in 
LTNPs, but the difference did not reach significance (p = 0.06, 
Fisher’s 2 ×  2 exact test), whereas the number of responders 
against HIV-1 subtype B Env peptides, Pol, Nef, Rev, and Vpu 
antigens was similar in both groups (Figure  2C). Although 
the magnitude of ADCC response is shown as % total NK cell 
activation (sum of % NK cells expressing CD107a and/or IFN-
γ), overall the distribution of CD107a and IFN-γ expression of 
activated NK cells by the NK cell-activating antibodies within 
the plasma of the LTNPs and progressors was found to be skewed 
toward higher IFN-γ expression in both groups (Table S2 in 
Supplementary Material).
We then analyzed whether the magnitude of the Env subtype 
C, Tat, and Gag-specific ADCC responses in the HIV-infected 
individuals correlated with CD4 T cell count and viral load; 
standard markers of HIV disease progression. Anti-Env ADCC 
responses were modestly correlated with CD4 T cell counts 
(r =  0.235, p =  0.02, Figure  3A). There was a trend toward 
higher CD4 T cell counts in subjects with higher Tat-specific 
ADCC responses (Spearman = 0.190, p = 0.07, Figure 3B). The 
plasma viral load values were negatively correlated with ADCC 
responses against Env-C specific ADCC (r = −0.367, p = 0.0006, 
Figure 3C) and Tat (r = −0.263, p = 0.016, Figure 3D) antigens. 
Also, a significant association between Env-C ADCC responses 
and lower plasma viral load was observed when only LTNP group 
was separately analyzed (Spearman r = −0.377; p = 0.04). Besides 
this, the median plasma viral load values (calculated based on 
annual viral load values obtained during the follow-up period) 
among LTNPs were also negatively correlated with ADCC 
responses against Env-C peptide pool (r = −0.505, p = 0.004). 
There was no significant correlation between CD4 T cell counts 
or viral load values with the magnitude of Gag-specific ADCC 
responses (data not shown). Our definition of LTNPs was immu-
nological (preserved CD4 T cell counts for at least 7 years) rather 
than virological. Hence, to further study the role of Env-specific 
ADCC in control of viral load, we divided the LTNP cohort 
into those with low-level viremia (median VL load <2,000 RNA 
copies/ml during follow-up) and with higher viral loads (median 
>2,000 RNA copies/ml). The magnitude of ADCC response 
against envelope C peptide pool was similar in the viremic 
controllers and non-controllers within LTNP (p = 0.15). Out of 
five responders to V3 loop epitope from LTNP, four were viremic 
controller subgroup as against only one was from non-controller 
(Figure 3E).
The aDcc responses in lTnPs have 
higher Breadth
The ability of ADCC responses to recognize diverse HIV strains 
is likely to improve the effectiveness of ADCC antibodies as a 
prevention strategy. Hence, to study the breadth of the ADCC 
antibody specificities, we analyzed whether LTNPs and progres-
sors recognized both subtype C and B Env peptide pools. We 
found that of the 34 LTNPs, 20.6% (N = 7) had ADCC responses 
against both HIV-1 C and B Env peptides, whereas only 3.4% 
(2/58) of the progressors showed response against both B and C 
Env peptides (p < 0.01 by Fisher’s 2 × 2 exact test, Figure 4A).
Combinations of broad ADCC responses might also con-
tribute to slow HIV progression given our findings on Env- and 
Tat-specific ADCC responses as mentioned above. To study this, 
we analyzed both the cohorts that had positive ADCC responses 
to 0, 1, 2, 3 or >3 of the HIV antigens represented by peptide 
FigUre 2 | continued
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FigUre 2 | characteristics of aDcc responses in indian long-term non-progressors (lTnPs) and progressors. Vertical scatter plots (error bars—mean 
with SEM) denote magnitudes of ADCC-mediated natural killer (NK) cell activation in responders from LTNPs and progressors against HIV-1 antigen peptide pools. 
Magnitude of ADCC response against (a) structural proteins: HIV-1 B Env, HIV-1 C Env, HIV-1 C Gag, and HIV-1 B Pol and (B) accessory proteins: HIV-1 B Tat, Rev, 
Nef, and Vpu. The magenta colored dots represent ADCC responders (fulfilled both criteria mentioned in Materials and Methods section). The non-specific 
recognition of the peptides as indicated by the % NK cell activation by HIV-negative plasma after stimulation by same peptide pools is indicated in black dots.  
(c) Bar diagram represents the frequency of responses in both cohorts against HIV-1 B and C Env, HIV-1 C Gag, HIV-1 B Pol, Tat, Rev, Nef, and Vpu. The 
frequencies were higher in LTNPs in case of responses against Env subtype C and Gag, whereas a trend of higher tat-specific responses was observed in LTNPs 
although not significant (Fisher’s exact 2 × 2 test).
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pools. We found that the ADCC responses in the LTNPs showed 
significantly greater breadth compared to the progressors. A total 
of 21% of LTNPs showed responses against more than three anti-
gens, compared to 7% in progressors (chi square test, p < 0.0001, 
Figure 4B).
indian lTnPs showed Preferential 
recognition of env-c V3 and Tat epitopes
ADCC responses targeting specific epitopes may be beneficial 
in HIV control, similar to that observed with specific CD8+ 
CTL responses. To identify epitopes recognized by the ADCC 
antibodies from the Indian LTNPs, we used a matrix approach 
using subpools of peptides. The peptide pools in the matrix were 
designed in such a way that a single peptide was common in 
both the pools. ADCC epitopes identified in the matrix approach 
were then confirmed by NK cell activation assay using the single 
peptide present in both the pools to which the response was 
observed. We studied epitopes from Env-C and Tat antigens, as 
the responses to these antigens were associated with lower plasma 
viral load and also were higher in frequencies and magnitudes 
in the LTNP cohort. Due to the scarcity of the samples from 
the progressor group, we mapped the potential ADCC epitopes 
only in LTNPs and only the frequently recognized peptides 
(when recognized by 3 or more than 3 LTNPs) were tested in 
progressors.
The consensus Env-C overlapping peptides were 212 in 
number and the number of consensus Tat B peptides were 
23. Out of 212 Env-C peptides, 153 peptides were recognized 
by ADCC antibodies from 10 LTNPs and 16 out of 23 Tat B 
peptides were recognized by 3 LTNPs (Table  2). One LTNP 
showed response to Env and Tat peptides. It was observed 
that the conserved C1, C2, C4, and C5 region and the variable 
V3, V4, and V5 and a few CD4 binding sites were recognized 
by the ADCC antibodies from Indian LTNPs (Table  2). In 
FigUre 3 | aDcc responses were associated with higher cD4 count and lower plasma viral load. CD4 counts at the testing visit (N = 92) (X axis) with 
envelope C peptide pool (Y axis) (p = 0.02) (a) and Tat-specific ADCC responses (Y axis) (p = 0.07) (B). (c,D) Association of plasma viral load at the testing visit 
(N = 92) with ADCC response against Env-C peptide pool and Tat B peptide pool, respectively. (e) Magnitude of envelope C-specific ADCC response in viremic 
controllers and non-controllers within long-term non-progressors (LTNPs). The magnitude of ADCC responses [% natural killer cell activation] was comparable in 
between the groups, but the number of responders to envelope C was high in viremic controllers (8 out of 12) (plasma viral load <2,000 copies/ml) as against 4 out 
of 22 LTNPs with plasma viral load >2,000 copies/ml. Additionally, the preferential recognition of V3 region (aa 288–330) as indicated by blue dot was seen in four 
out of eight responders from viremic controller LTNPs as against only one out of four responders from non-controllers.
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the gp41 region, both transmembrane and cytoplasmic tail 
regions were also identified. The Env-C V3 region (aa 288–330: 
LNESVEIVCTRPNNNTRKSIRIGPGQTGDIIGDIRQAHC) 
was preferentially identified by Indian LTNPs (5/10 Env-C 
responders) (Table 2). This region has also been previously iden-
tified by the monoclonal antibodies (694/98D, 4117C, 41148D, 
CH22, CH23) generated from the HIV-1 B-infected ADCC 
responders (19–22). None of the progressors identified this 
peptide (p = 0.0002 by Fisher’s exact test) (Table 3), indicating 
a potential role of ADCC antibodies recognizing this region in 
virus control. Additionally, Indian LTNPs also showed recogni-
tion of novel antigenic stretches from the signal peptide region 
(aa 1–15), CD4 binding sites (aa 113–117 and aa 361–366), C2 
region (aa 250–288), aa C3 (aa 331–360), V4, C4, and V5 region 
(aa 381–470), and fusion peptide region of gp41 (aa 510–570) 
(Table  2). Three “Tat” regions (peptide no. 8, 12–13, 20–22) 
were recognized by three (8.82%) LTNPs. None of the progres-
sors identified these regions (Fisher’s exact test: p < 0.05 for all) 
(Table 3).
DiscUssiOn
Understanding the immune responses controlling HIV repli-
cation and disease progression will be critical in the develop-
ment of improved preventive and curative strategies. LTNPs 
and elite controllers can be considered as a model for slow 
disease progression with better virus control. In addition to 
cellular immunity, there is emerging literature on the role of 
functional antibodies in virus control in these populations (23, 
24). Ackerman and colleagues recently showed that subtype 
B-infected elite controllers with spontaneous virus control 
have a combination of various antibody effector mechanisms, 
including ADCC (25). Our study showed that the anti-Env 
ADCC responses were significantly higher in LTNPs with low 
plasma viral load (<2,000 copies/ml), suggesting a probable 
role for ADCC in controlling viral replication in subtype C HIV 
infections in India. We also found that ADCC antibodies from 
LTNPs were significantly more likely to identify more than one 
antigen simultaneously compared to progressors. Broad CTL 
FigUre 4 | lTnPs showed cross clade as well as broad aDcc 
responses. (a) Percentage of the responders (Y axis) to both Env-C and -B 
peptides is significantly higher in LTNPs as compared to the progressors 
(p = 0.01 in a 2 × 2 Fischer’s exact test). (B) The breadth of the ADCC 
response. The number of human immunodeficiency virus antigens (Y axis) 
recognized by ADCC antibodies from LTNPs were significantly higher than 
the number of antigens recognized by progressors (chi square test, 
p < 0.0001).
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have been reported by other groups studying subjects infected 
with HIV-1 subtypes B and A (5, 29–31), suggesting that the role 
of ADCC responses in controlling viral multiplication holds true 
across multiple clades.
The envelope protein is frequently targeted by ADCC anti-
bodies from subtype B-infected individuals and non-human 
primates (22, 32–37). We have shown that ADCC responses 
in Indian LTNPs also preferentially target Env-C region, con-
firming a key role for Env-specific ADCC responses in virus 
control. The use of overlapping peptide pools allowed us to 
map Env-specific ADCC responses to individual linear peptide 
epitopes. We found ADCC antibodies from Indian LTNPs 
recognized both variable and conserved regions of Env-C 
antigens. Different ADCC monoclonal antibodies generated 
from HIV-1 subtype B infected population were shown to be 
specific to CD4-induced epitopes (19, 38). In our LTNP cohort, 
we found that the peptides spanning the V3 region of Env were 
commonly targeted (5/10 of Env-C responders), indicating that 
the antibodies recognizing HIV-1 Env region independent of 
CD4 binding region might also be important in viral control. 
Indeed, in our study, four of the five LTNPs who recognized 
this epitope have undetectable plasma viral load (Figure  3E). 
The main caveat of the anti-variable loop ADCC responses is 
the variability in this region across viruses. However, detection 
of these responses in HIV-1 LTNPs emphasizes a potential role 
of anti-V3 ADCC responses in viral control in HIV-1 C-infected 
patients. Effective V3-specific ADCC antibodies could also have 
neutralizing capacity, providing an additional level of immune 
control (39). Additional research is required to know whether 
these antibodies also have a role in clearing of latent reservoirs 
where the virus can downregulate CD4, making it inaccessible 
for CD4-dependent ADCC antibodies. It was also observed 
that a few previously identified regions such as V2 region of 
gp120 and immunodominant region of gp41 were not recog-
nized by Indian LTNPs (22). This differential recognition of 
ADCC epitopes by individuals infected with different subtypes 
has implications for vaccine designs and immunotherapeutic 
strategies. The importance of recognition of these epitopes 
could be assessed in longitudinal samples to determine whether 
the sustained recognition of these regions influences disease 
progression.
Our finding that Indian LTNPs develop Tat-specific ADCC 
responses was novel and unexpected although only 4 of 34 
LTNPs showed Tat-specific response. A number of researchers 
have reported ADCC responses against Nef, Vpu, and Pol (7, 40, 
41), but in our cohort, we found significantly higher and more 
common recognition of Tat peptides in LTNPs. Tat is one of the 
earliest expressed proteins in HIV-1 infection and is responsible 
for efficient transcription (42–45). It has been shown that the 
presence of Tat-specific CTLs and/or anti-Tat antibody is asso-
ciated with control of viral replication and slow progression to 
AIDS (46–48). In non-human primate models, greater protection 
was correlated with Tat- and Env-binding antibodies along with 
higher ADCC and ADCVI activities (49). The ADCC antibodies 
generated against the antigen expressed early in the life cycle 
might be able to control viral replication early. It will be interest-
ing to study Tat-specific monoclonal and polyclonal antibodies 
responses have been shown to be associated with slow or no 
progression (26–28). It might be possible that broad ADCC 
responses limit opportunities for immune escape from ADCC 
reducing the disease progression (9). It will be interesting to 
estimate ADCC responses to various epitopes over time in this 
cohort to confirm this hypothesis.
Further characterization of anti-Env and anti-Tat ADCC 
responses in our Indian LTNP cohort found that they were 
associated with higher CD4 counts and lower plasma viral loads 
at the time of study visit and also with lower median plasma viral 
load calculated for the entire follow-up period. Similar findings 
TaBle 3 | comparison of envelope c peptides and tat B regions recognized by indian long-term non-progressors (lTnPs).
hiV-1 protein Peptide no.* sequence no. responder/no tested 
(% of response)
Fisher’s exact test
lTnP Progressor
Envelop C (consensus HIV-1 C) E-6 FWMLMICNVMGNLWV 1/34 (2.9%) 0/58 0.369 (NS)
E12 KEAKTTLFCASDAKA 1/34 (2.9%) 0/58 0.369 (NS)
E-73–80 LNESVEIVCTRPNNNTRKSIRIGPGQTGDIIGDIRQAHC 8/34 (23.5%) 0/58 0.0002
Tat (consensus HIV-1 B) T-8 KCCFHCQVCFITKGL 3/34 (8.82%) 0/58 0.0477
T-12, 13 ISYGRKKRRQRRRAPQDSQ
T-20, 21, 22 PRGDPTGPKESKKKVERETETDP
TaBle 2 | envelope (consensus hiV-1 c) peptides and tat (consensus hiV-1 B) regions recognized by indian long-term non-progressors (lTnPs).
lTnP number env-c Tat B
no of peptides 
recognized
Protein region no of peptides 
recognized
Protein region
LTNP 8 0 4 Nuclear localization region
LTNP 10 30 C2–V3 region –
LTNP 14 4 V3, C3 –
LTNP 23 17 C1, C3, V4, C5 cytoplasmic tail of gp41 –
LTNP 30 1 V3 –
LTNP 34 24 Signal peptide, C1 and C2 –
LTNP 37 8 Fusion peptide region –
LTNP 50 0 11 Nuclear localization region
LTNP 45 1 V3 –
LTNP 48 4 C1, V3 –
LTNP 54 2 C1 –
LTNP 58 66 C1, V3 C3 region with Cd4 binding site in C3, V4, C4, C5 fusion peptide 
region cytoplasmic tail and cytoplasmic tail in gp41 region
5 Nuclear
Localization
Region
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to determine whether antibodies generated against individual Tat 
epitopes can lyse HIV-infected cells and control HIV infection 
in vitro. We have used subtype B Tat peptides in the study as sub-
type C Tat peptides were not available. This is the limitation of the 
study. However, we carried out a blast analysis of Tat sequences 
of consensus subtype C and consensus subtype B, which showed 
that the three Tat epitope regions identified by Indian LTNPs had 
69, 93, and 82% similarity (Figure S2 in Supplementary Material). 
Given our findings, future studies using consensus subtype C Tat 
peptides or autologous peptide sets based on individual viruses 
are now warranted.
Since the ADCC activity observed in the NK cell activation 
assays significantly correlate with a functional killing assay (11), 
we can speculate that NK cell activating antibodies from Indian 
LTNPs would have an ability to kill HIV-infected cells in vivo; 
future studies are needed to study the efficiency of target cell 
killing by these antibodies.
In conclusion, ADCC responses have been characterized in 
Indian LTNPs for the first time. The findings added to the global 
data and confirm the association of broad ADCC responses in 
viral containment across different subtypes. The frequently rec-
ognized peptides from the V3 loop of Env-C and Tat antigen by 
LTNPs with controlled viral replication warrants further studies 
to understand their probable role in clearing the latent infection 
and also in HIV protection.
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